Advertisement
News
Advertisement

Genzyme-marketed test sees positive results

Tue, 07/17/2012 - 12:00am
Mass High Tech: The Journal of New England Technology

A gene expression classification test developed by San Fransisco-based Veracyte Inc., and being co-marketed by Genzyme, a Sanofi company, helps reduce unnecessary surgery in patients at risk for thyroid cancer, according to a study published by the journal, Thyroid.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading